Yurttutan, SadikOzdemir, RamazanCanpolat, Fuat EmreOncel, Mehmet YektaUnverdi, Hatice GermenUysal, BulentErdeve, Omer2024-08-042024-08-0420140179-03581437-9813https://doi.org/10.1007/s00383-013-3415-4https://hdl.handle.net/11616/96324Tissue damage in necrotizing enterocolitis (NEC) of infants occurs as a result of an uncontrolled inflammatory response. The aim of this study was to investigate any potential anti-inflammatory effects that Etanercept may have on the inflammatory response in an experimental NEC model in newborn rats. Newborn pups were randomized into three groups immediately after birth (Control, NEC + Placebo and NEC + Etanercept). Pups in the NEC + Placebo and NEC + Etanercept groups were subjected to an NEC-inducing protocol (hypercarbia, hypothermia and hyperoxia) twice a day for 3 days. Pups in the NEC + Etanercept group were given an intraperitoneal injection of Etanercept. Rats were harvested for biochemical and histopathological examinations. The histopathological injury score of rats in the NEC + Placebo group was significantly higher compared to the NEC + Etanercept and Control groups (p < 0.05 for both comparisons). Tissue levels of tumor necrosis factor-alpha, interleukin-1 beta, and malondialdehyde were higher in the placebo group compared to the Etanercept group. Our results suggest that Etanercept attenuates intestinal tissue damage in NEC by reducing inflammation and blocking the production of free-oxygen radicals, while also reducing tissue levels of tumor necrosis factor-alpha and interleukin-1 beta.eninfo:eu-repo/semantics/closedAccessNecrotizing enterocolitisEtanerceptTumor necrosis factor-alphaArticle30171772407220210.1007/s00383-013-3415-42-s2.0-84892606356Q2WOS:000329237900010Q3